Partnerships
IMU Powers Drug Discovery & Clinical Breakthroughs
IMU collaborates with clinical research groups, pharmaceutical, biotech and diagnostics companies to identify and deploy clinically actionable immune signatures that advance precision medicine.
Partnering with IMU
01
Discovering clinically actionable systems-level immune signatures
- Discovery of novel immune signatures of disease
- Discovery of mDiscovery of mechanistic insights into treatment success, resistance and toxicity
- Identification of new therapeutic targets and immune-driven pathways
- Identification of bIdentification of biomarkers for early diagnosis and disease endotyping
02
Increasing success in drug discovery and development
IMU collaborates with pharmaceutical and biotech partners throughout the drug discovery and clinical development journey, across a range of therapeutic areas. These collaborations support diverse applications — from deepening the understanding of disease mechanisms, identifying novel therapeutic targets, supporting translational studies and enhancing clinical trial success rates through informing patient stratification and selection.
03
Delivering immune driven precision medicine
IMU is advancing its own clinical programs while also partnering with diagnostic, biotech and pharma companies to translate immune signatures into clinical practice.
